The Journal of Allergy and Clinical Immunology
Volume 119, Issue 1 , Pages 64-72 , January 2007

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial

  • Christine A. Sorkness, PharmD

      Affiliations

    • Clinical Science Center, University of Wisconsin, Madison
    • Corresponding Author InformationReprint requests: Christine A. Sorkness, PharmD, K4/950 University of Wisconsin Clinical Science Center, 600 Highland Avenue, Madison, WI 53792-3244.
    • ,
  • Robert F. Lemanske Jr., MD

      Affiliations

    • Clinical Science Center, University of Wisconsin, Madison
    • ,
  • David T. Mauger, PhD

      Affiliations

    • Department of Health Evaluation Sciences, Pennsylvania State University, Hershey
    • ,
  • Susan J. Boehmer, MA

      Affiliations

    • Department of Health Evaluation Sciences, Pennsylvania State University, Hershey
    • ,
  • Vernon M. Chinchilli, PhD

      Affiliations

    • Department of Health Evaluation Sciences, Pennsylvania State University, Hershey
    • ,
  • Fernando D. Martinez, MD

      Affiliations

    • From the Arizona Respiratory Center, University of Arizona, Tucson
    • ,
  • Robert C. Strunk, MD

      Affiliations

    • Department of Pediatrics, Washington University, St Louis
    • ,
  • Stanley J. Szefler, MD

      Affiliations

    • Department of Pediatrics, National Jewish and Research Center and University of Colorado Health Sciences Center, Denver
    • ,
  • Robert S. Zeiger, MD, PhD

      Affiliations

    • Department of Pediatrics, University of California–San Diego
    • Department of Allergy, Kaiser Permanente, San Diego
    • ,
  • Leonard B. Bacharier, MD

      Affiliations

    • Department of Pediatrics, Washington University, St Louis
    • ,
  • Gordon R. Bloomberg, MD

      Affiliations

    • Department of Pediatrics, Washington University, St Louis
    • ,
  • Ronina A. Covar, MD

      Affiliations

    • Department of Pediatrics, National Jewish and Research Center and University of Colorado Health Sciences Center, Denver
    • ,
  • Theresa W. Guilbert, MD

      Affiliations

    • From the Arizona Respiratory Center, University of Arizona, Tucson
    • ,
  • Gregory Heldt, MD

      Affiliations

    • Department of Pediatrics, University of California–San Diego
    • ,
  • Gary Larsen, MD

      Affiliations

    • Department of Pediatrics, National Jewish and Research Center and University of Colorado Health Sciences Center, Denver
    • ,
  • Michael H. Mellon, MD

      Affiliations

    • Department of Allergy, Kaiser Permanente, San Diego
    • ,
  • Wayne J. Morgan, MD

      Affiliations

    • From the Arizona Respiratory Center, University of Arizona, Tucson
    • ,
  • Mark H. Moss, MD

      Affiliations

    • Clinical Science Center, University of Wisconsin, Madison
    • ,
  • Joseph D. Spahn, MD

      Affiliations

    • Department of Pediatrics, National Jewish and Research Center and University of Colorado Health Sciences Center, Denver
    • ,
  • Lynn M. Taussig, MD

      Affiliations

    • Department of Pediatrics, National Jewish and Research Center and University of Colorado Health Sciences Center, Denver
    • ,
  • for the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute

Received 9 June 2006 ,Revised 30 August 2006 ,Accepted 5 September 2006.

References 

  1. National Asthma Education and Prevention Program . Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics—2002. J Allergy Clin Immunol. 2002;110(suppl):S141–S219[Erratum, J Allergy Clin Immunol 2003;111:466]
  2. The Childhood Asthma Management Program Research Group . Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–1063
  3. Beck-Ripp J, Griese M, Arenz S, Koring C, Pasqualoni B, Bufler P. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J. 2002;19:1015–1019
  4. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064–1069
  5. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year old children: a randomized, double-blind trial. JAMA. 1998;279:1181–1186
  6. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Response profiles to fluticasone and montelukast in mild to moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45–52
  7. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233–242
  8. Garcia MLZ, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the Mosaic Study. Pediatrics. 2005;116:360–369
  9. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA. 2001;285:2594–2603
  10. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol. 1995;75:423–428
  11. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002;34:342–350
  12. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med. 1998;158:213–219
  13. Verberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared to beclomethasone in children with asthma. Am J Respir Crit Care Med. 1997;156:688–695
  14. Lee DK, Currie GP, Hall IP, Lima JJ, Lipworth BJ. The arginine-16 beta 2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol. 2004;57:68–75
  15. Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology. 2004;9:528–534
  16. Masoli M, Weatherall M, Beasley R. Fluticasone given once versus twice a day: meta-analysis. Respirology. 2005;10:183–188
  17. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152:1107–1136
  18. Chapter 711 . Dissolution. In: The United States Pharmacopeia/The National Formulary (USP 28/NF23). Rockville (MD): United States Pharmacopeial Convention, Inc; 2005;p. 2412–2415
  19. Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112:883–892
  20. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–907
  21. Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orave J, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med. 2005;118:649–657
  22. Ostrom NK, Decotis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza R, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147:213–220
  23. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344:219–224
  24. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481–1488
  25. Pauwels RA, Löfdahl CG, Postma DA, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405–1411
  26. Sont JK, Willems LN, Bel EH, Van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma using airway hyperreponsiveness as an additional guide to long term treatment. Am J Respir Crit Care Med. 1999;159:1043–1051
  27. Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, et al. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by Diskus device in patients treated with or without inhaled corticosteroids. J Allergy Clin Immunol. 2000;105:1153–1161
  28. Shigyo M, Inoue H, Honda Y, Takata S, Iwanaga T, Koto H, et al. Once-daily administration of fluticasone propionate does not worsen controlled airway responsiveness in patients with asthma. Respiration. 2005;72:480–485
  29. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323:1–8
  30. LaForce CF, Pearlman DS, Ruff ME, Silvers WS, Weinstein SW, Clements DS, et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann Allergy Asthma Immunol. 2000;85:407–415
  31. Li AM, Tsang TW, Chan K, Chan DF, Sung RY, Fok TF. Once-daily fluticasone propionate in stable asthma: study on airway inflammation. J Asthma. 2006;43:107–111
  32. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26
  33. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904–912

 Supported by grants HL064307, HL64288, HL064295, HL64287, and HL064305 from the National Heart, Lung and Blood Institute. This study was performed in part by the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), National Jewish Medical and Research Center (M01 RR00051), and the University of Wisconsin (M01 RR03186).Disclosure of potential conflict of interest: C. A. Sorkness has consultant arrangements with GlaxoSmithKline and AstraZeneca, has received grant support from GlaxoSmithKline and Pharmaxis, and is on the speakers' bureau for GlaxoSmithKline and Genentech. R. F. Lemanske has consultant arrangements with GlaxoSmithKline, Merck, AstraZeneca, Aventis, and Novartis, has received grant support from the National Heart, Lung, and Blood Institute (NHLBI), and is on the speakers' bureau for Merck, AstraZeneca, GlaxoSmithKline, and Aventis. D. T. Mauger, S. J. Boehmer, and V. M. Chinchilli have received grant support from the National Institutes of Health (NIH). F. D. Martinez has had consultant arrangements with Genentech and Pfizer, has served on the advisory board for Merck, and has received an honorarium for a lecture at a meeting sponsored by Merck. S. J. Szefler has consultant arrangements with AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck, and has received grant support from the NIH, NHLBI, National Institute of Allergy and Infectious Diseases, and Ross Pharmaceuticals. R. S. Zeiger has consultant arrangements with Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sanofi-Aventis, and has received grant support from AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Aventis, and TEVA Pharmaceuticals. L. B. Bacharier has received grant support from the NIH and NHLBI, and is on the speakers' bureau for Merck, GlaxoSmithKline, AstraZeneca, and Genentech. R. A. Covar has received grant support from AstraZeneca. T. W. Guilbert has participated on an advisory board sponsored by GlaxoSmithKline and as a consultant in the design of Continuing Medical Education (CME) courses and for asthma for the Innovia Medical Educational Institute, and has received consultant fees from GlaxoSmithKline and stocks or revenue from speakers' bureaus, research, or grant activities from GlaxoSmithKline, AstraZeneca, Merck, and Pfizer, and is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, SOMA Medical Education (CME), Innovia Medical Education Institute (CME), Antidote (formerly Medical World Conferences, CME), and Health Matters. G. Larsen has consultant arrangements with GlaxoSmithKline and Schering Plough, and has received grant support from the NIH. M. H. Mellon is on the speakers' bureau for AstraZeneca, Schering Plough, and Altana. W. J. Morgan has consultant arrangements with Genentech and has patent licensing arrangements with the Wisconsin Alumni Research Foundation. J. D. Spahn has consultant arrangements with GlaxoSmithKline and AstraZeneca, has received grant support from Merck, AstraZeneca, and GlaxoSmithKline, and is on the speakers' bureau for GlaxoSmithKline. L. M. Taussig has consultant arrangements with GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)02122-1

doi: 10.1016/j.jaci.2006.09.042

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 1 , Pages 64-72 , January 2007

Article Tools

* Image Usage & Resolution